-
1
-
-
34347388306
-
United States Renal Data System
-
Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006, accessed Feb 7
-
United States Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006. www.usrds.org/adr.htm (accessed 2007 Feb 7).
-
(2007)
USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States
-
-
-
2
-
-
34347370550
-
-
National Institute of Diabetes and Digestive and Kidney Diseases. Kidney and urologic diseases statistics for the United States. kidney.niddk.nih.gov/ kudiseases/pubs/kustats/index.htm (accessed 2007 Feb 11).
-
National Institute of Diabetes and Digestive and Kidney Diseases. Kidney and urologic diseases statistics for the United States. kidney.niddk.nih.gov/ kudiseases/pubs/kustats/index.htm (accessed 2007 Feb 11).
-
-
-
-
3
-
-
45849155948
-
Estimating workforce and training requirements for nephrologists through the year 2010
-
Ad Hoc Committee on Nephrology Manpower Needs, May; , passim
-
Ad Hoc Committee on Nephrology Manpower Needs. Estimating workforce and training requirements for nephrologists through the year 2010. J Am Soc Nephrol. 1997 May; 8(5 suppl 9):S9-13, i-xxii, 1-32 passim.
-
(1997)
J Am Soc Nephrol
, vol.8
, Issue.5 SUPPL. 9
-
-
-
4
-
-
33646520143
-
Managing the burden of chronic kidney disease
-
Thorp ML, Eastman L, Smith DH et al. Managing the burden of chronic kidney disease. Dis Manag. 2006; 9:115-21.
-
(2006)
Dis Manag
, vol.9
, pp. 115-121
-
-
Thorp, M.L.1
Eastman, L.2
Smith, D.H.3
-
5
-
-
33751051945
-
Survey of care provided by ambulatory care pharmacists to patients with chronic kidney disease
-
Bennett RE, DeHart RM, Lauderdale SA. Survey of care provided by ambulatory care pharmacists to patients with chronic kidney disease. Am J Health-Syst Pharm. 2006; 63:2123-7.
-
(2006)
Am J Health-Syst Pharm
, vol.63
, pp. 2123-2127
-
-
Bennett, R.E.1
DeHart, R.M.2
Lauderdale, S.A.3
-
6
-
-
33646345152
-
KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease
-
National Kidney Foundation
-
National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47(5 suppl 3):S11-145.
-
(2006)
Am J Kidney Dis
, vol.47
, Issue.5 SUPPL. 3
-
-
-
7
-
-
0036894205
-
Improving blood pressure control in a pharmacist-managed hypertension clinic
-
Vivian EM. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy. 2002; 22:1533-40.
-
(2002)
Pharmacotherapy
, vol.22
, pp. 1533-1540
-
-
Vivian, E.M.1
-
8
-
-
0035174174
-
Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic
-
Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Pharmacotherapy. 2001; 21:1337-44.
-
(2001)
Pharmacotherapy
, vol.21
, pp. 1337-1344
-
-
Okamoto, M.P.1
Nakahiro, R.K.2
-
9
-
-
1942503169
-
Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic
-
Cioffi ST, Caron MF, Kalus JS et al. Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic. Ann Pharmacother. 2004; 38:771-5.
-
(2004)
Ann Pharmacother
, vol.38
, pp. 771-775
-
-
Cioffi, S.T.1
Caron, M.F.2
Kalus, J.S.3
-
10
-
-
33746333865
-
Development and clinical outcomes of pharmacist-managed diabetes care clinics
-
Morello CM, Zadvorny EB, Cording MA et al. Development and clinical outcomes of pharmacist-managed diabetes care clinics. Am J Health-Syst Pharm. 2006; 63:1325-31.
-
(2006)
Am J Health-Syst Pharm
, vol.63
, pp. 1325-1331
-
-
Morello, C.M.1
Zadvorny, E.B.2
Cording, M.A.3
-
11
-
-
33751040268
-
Outcomes of pharmacist-managed diabetes care services in a community health center
-
Scott DM, Boyd ST, Stephan M et al. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health-Syst Pharm. 2006; 63:2116-22.
-
(2006)
Am J Health-Syst Pharm
, vol.63
, pp. 2116-2122
-
-
Scott, D.M.1
Boyd, S.T.2
Stephan, M.3
-
12
-
-
0036828970
-
Establishing pharmaceutical services on a renal dialysis unit
-
Naughton CA. Establishing pharmaceutical services on a renal dialysis unit. Am J Health-Syst Pharm. 2002; 59:2111-2.
-
(2002)
Am J Health-Syst Pharm
, vol.59
, pp. 2111-2112
-
-
Naughton, C.A.1
-
13
-
-
22044451595
-
Impact of a pharmacist-implemented anemia management in outpatients with end-stage renal disease in Japan
-
Kimura T, Arai M, Masuda H et al. Impact of a pharmacist-implemented anemia management in outpatients with end-stage renal disease in Japan. Biol Pharm Bull. 2004; 27:1831-3.
-
(2004)
Biol Pharm Bull
, vol.27
, pp. 1831-1833
-
-
Kimura, T.1
Arai, M.2
Masuda, H.3
-
14
-
-
0031040828
-
Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist
-
Grabe DW, Low CL, Bailie GR et al. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol. 1997; 47:117-21.
-
(1997)
Clin Nephrol
, vol.47
, pp. 117-121
-
-
Grabe, D.W.1
Low, C.L.2
Bailie, G.R.3
-
15
-
-
3342936430
-
A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients
-
Viola RA, Abbott KC, Welch PG et al. A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients. BMC Nephrol. 2002; 3:9.
-
(2002)
BMC Nephrol
, vol.3
, pp. 9
-
-
Viola, R.A.1
Abbott, K.C.2
Welch, P.G.3
-
16
-
-
0032572913
-
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
-
Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339:584-90.
-
(1998)
N Engl J Med
, vol.339
, pp. 584-590
-
-
Besarab, A.1
Bolton, W.K.2
Browne, J.K.3
-
17
-
-
27144498003
-
Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease
-
Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005; 16:2180-9.
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 2180-2189
-
-
Parfrey, P.S.1
Foley, R.N.2
Wittreich, B.H.3
-
18
-
-
0035012513
-
The CREATE trial - building the evidence
-
Eckardt KU. The CREATE trial - building the evidence. Nephrol Dial Transplant. 2001; 16(suppl 2):16-8.
-
(2001)
Nephrol Dial Transplant
, vol.16
, Issue.SUPPL. 2
, pp. 16-18
-
-
Eckardt, K.U.1
-
19
-
-
33750983605
-
Correction of anemia with epoetin alfa in chronic kidney disease
-
Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085-98.
-
(2006)
N Engl J Med
, vol.355
, pp. 2085-2098
-
-
Singh, A.K.1
Szczech, L.2
Tang, K.L.3
-
20
-
-
33751002326
-
Normalization of hemoglobin level in patients with chronic kidney disease and anemia
-
Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355:2071-84.
-
(2006)
N Engl J Med
, vol.355
, pp. 2071-2084
-
-
Drüeke, T.B.1
Locatelli, F.2
Clyne, N.3
-
21
-
-
33751006109
-
Correction of anemia - payoffs and problems
-
Remuzzi G, Ingelfinger JR. Correction of anemia - payoffs and problems. N Engl J Med. 2006; 355:2144-6.
-
(2006)
N Engl J Med
, vol.355
, pp. 2144-2146
-
-
Remuzzi, G.1
Ingelfinger, J.R.2
-
22
-
-
23144442156
-
Extended epoetin alfa dosing in chronic kidney disease patients: A retrospective review
-
Germain M, Ram CV, Bhaduri S et al. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant. 2005; 20:2146-52.
-
(2005)
Nephrol Dial Transplant
, vol.20
, pp. 2146-2152
-
-
Germain, M.1
Ram, C.V.2
Bhaduri, S.3
-
23
-
-
23144460027
-
Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study
-
Provenzano R, Bhaduri S, Singh AK et al. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol. 2005; 64:113-23.
-
(2005)
Clin Nephrol
, vol.64
, pp. 113-123
-
-
Provenzano, R.1
Bhaduri, S.2
Singh, A.K.3
-
24
-
-
18744363354
-
Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease
-
Ling B, Walczyk M, Agarwal A et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005; 63:327-34.
-
(2005)
Clin Nephrol
, vol.63
, pp. 327-334
-
-
Ling, B.1
Walczyk, M.2
Agarwal, A.3
-
25
-
-
34347373168
-
Darbepoetin alfa (DbA) in patients (pts) with chronic kidney disease (CKD) once monthly (QM) clinical experience with SureClick
-
Presented at the San Diego, CA: November 14-19
-
Sousa A, Vinhas J. Darbepoetin alfa (DbA) in patients (pts) with chronic kidney disease (CKD) once monthly (QM) clinical experience with SureClick. Presented at the American Society of Nephrology Annual Meeting and Scientific Exposition; San Diego, CA: November 14-19, 2006.
-
(2006)
American Society of Nephrology Annual Meeting and Scientific Exposition
-
-
Sousa, A.1
Vinhas, J.2
-
26
-
-
33750513406
-
Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis
-
Hoggard J, Crouch T, McMurray S et al. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin. 2006; 22:2023-30.
-
(2006)
Curr Med Res Opin
, vol.22
, pp. 2023-2030
-
-
Hoggard, J.1
Crouch, T.2
McMurray, S.3
-
27
-
-
34347373973
-
Outpatient RN + pharmacist-driven anemia clinic in stage 3-4 CKD: Efficacy and impact on disease progression
-
Presented at the San Diego, CA: November 14-19
-
Price M, Holdener K, Leverson G. Outpatient RN + pharmacist-driven anemia clinic in stage 3-4 CKD: efficacy and impact on disease progression. Presented at the American Society of Nephrology Annual Meeting and Scientific Exposition; San Diego, CA: November 14-19, 2006.
-
(2006)
American Society of Nephrology Annual Meeting and Scientific Exposition
-
-
Price, M.1
Holdener, K.2
Leverson, G.3
-
28
-
-
2942746431
-
-
Anon. Section IV. Failure to respond to treatment. Nephrol Dial Transplant. 2004; 19(suppl 2):ii32-ii36. www.ndt-educational.org/images/ New%20EBPG%20Anaemia%20Part%20III.pdf (accessed 2007 Feb 11).
-
Anon. Section IV. Failure to respond to treatment. Nephrol Dial Transplant. 2004; 19(suppl 2):ii32-ii36. www.ndt-educational.org/images/ New%20EBPG%20Anaemia%20Part%20III.pdf (accessed 2007 Feb 11).
-
-
-
-
29
-
-
33750970834
-
Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: A randomised, multicentre, multiple-dose, phase II study
-
de Francisco AL, Sulowicz W, Klinger M et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract. 2006; 60:1687-96.
-
(2006)
Int J Clin Pract
, vol.60
, pp. 1687-1696
-
-
de Francisco, A.L.1
Sulowicz, W.2
Klinger, M.3
-
30
-
-
34347374577
-
CERA (continuous erythropoiesis receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every four weeks
-
Presented at the, St. Louis, MO: October 29-November 1, Abstract SU-PO051
-
Locatelli F, Villa G, Arias M et al. CERA (continuous erythropoiesis receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every four weeks. Presented at the 37th Annual Meeting and Scientific Exposition of the American Society of Nephrology, St. Louis, MO: October 29-November 1, 2004. Abstract SU-PO051.
-
(2004)
37th Annual Meeting and Scientific Exposition of the American Society of Nephrology
-
-
Locatelli, F.1
Villa, G.2
Arias, M.3
-
31
-
-
34347395454
-
CERA (continuous erythropoietin receptor activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race, or diabetic status
-
Presented at the Nashville, TN: April 2-5
-
Dutka P, Tilocca P. CERA (continuous erythropoietin receptor activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race, or diabetic status. Presented at the American Nephrology Nurses' Association 37th National Symposium; Nashville, TN: April 2-5, 2006.
-
(2006)
American Nephrology Nurses' Association 37th National Symposium
-
-
Dutka, P.1
Tilocca, P.2
-
32
-
-
33845630518
-
Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis
-
Provenzano R, Besarab A, Macdougall IC et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis. J Am Soc Nephrol. 2005; 16:760A.
-
(2005)
J Am Soc Nephrol
, vol.16
-
-
Provenzano, R.1
Besarab, A.2
Macdougall, I.C.3
-
33
-
-
34347404971
-
CERA administered at extended intervals corrects anemia and maintains stable Hbg levels in patients with CKD not on dialysis
-
Presented at the San Diego, CA: November 14-19
-
MacDougall C, Walker R, Provenzano R et al. CERA administered at extended intervals corrects anemia and maintains stable Hbg levels in patients with CKD not on dialysis. Presented at the American Society of Nephrology Annual Meeting and Scientific Exposition; San Diego, CA: November 14-19, 2006.
-
(2006)
American Society of Nephrology Annual Meeting and Scientific Exposition
-
-
MacDougall, C.1
Walker, R.2
Provenzano, R.3
-
34
-
-
34347392188
-
Anemia management in pre-dialysis chronic kidney disease. A pharmacist-provided CKD anemia management clinic
-
Presented at the Las Vegas, NV: December 4
-
Joy M. Anemia management in pre-dialysis chronic kidney disease. A pharmacist-provided CKD anemia management clinic. Presented at the 40th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition; Las Vegas, NV: December 4, 2005.
-
(2005)
40th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition
-
-
Joy, M.1
-
35
-
-
0034918872
-
Management of patients with chronic renal insufficiency in the Northeastern United States
-
Kausz AT, Khan SS, Abichandani R et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol. 2001; 12:1501-7.
-
(2001)
J Am Soc Nephrol
, vol.12
, pp. 1501-1507
-
-
Kausz, A.T.1
Khan, S.S.2
Abichandani, R.3
-
36
-
-
34347405179
-
Iron preparations, oral
-
McEvoy GK, ed, Bethesda, MD: American Society of Health-System Pharmacists;
-
McEvoy GK, ed. Iron preparations, oral. In: AHFS Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1410-7.
-
(2007)
AHFS Drug Information 2007
, pp. 1410-1417
-
-
-
39
-
-
34347406833
-
Iron sucrose
-
McEvoy GK, ed, Bethesda, MD: American Society of Health-System Pharmacists;
-
McEvoy GK, ed. Iron sucrose. In: AHFS Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1417-8.
-
(2007)
AHFS Drug Information 2007
, pp. 1417-1418
-
-
-
40
-
-
34347383056
-
-
Venofer package insert. Shirley, NY: American Regent, Inc; October 2005
-
Venofer package insert. Shirley, NY: American Regent, Inc; October 2005.
-
-
-
-
41
-
-
34347392189
-
Sodium ferric gluconate
-
McEvoy GK, ed, Bethesda, MD: American Society of Health-System Pharmacists;
-
McEvoy GK, ed. Sodium ferric gluconate. In: AHFS Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1418-22.
-
(2007)
AHFS Drug Information 2007
, pp. 1418-1422
-
-
-
42
-
-
34347381611
-
-
Ferrlecit package insert. Corona, CA: Watson Pharma, Inc. September 2006
-
Ferrlecit package insert. Corona, CA: Watson Pharma, Inc. September 2006.
-
-
-
-
43
-
-
33947212276
-
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to i.v. iron with elevated ferritin (DRIVE) study
-
Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to i.v. iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol. 2007; 18:975-84.
-
(2007)
J Am Soc Nephrol
, vol.18
, pp. 975-984
-
-
Coyne, D.W.1
Kapoian, T.2
Suki, W.3
-
44
-
-
34347398350
-
Outpatient erythropoietin administered via a protocol-driven pharmacist-overseen program is associated with significant patient and economic benefits
-
Presented at the San Diego, CA: November 14-19
-
Akers GR, Brown BL, Roberts SS et al. Outpatient erythropoietin administered via a protocol-driven pharmacist-overseen program is associated with significant patient and economic benefits. Presented at the American Society of Nephrology Annual Meeting and Scientific Exposition; San Diego, CA: November 14-19, 2006.
-
(2006)
American Society of Nephrology Annual Meeting and Scientific Exposition
-
-
Akers, G.R.1
Brown, B.L.2
Roberts, S.S.3
|